搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
8 小时
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop ...
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
7 小时
Biotech Stocks Facing FDA Decision In December 2024
The FDA has approved 43 novel drugs so far this year (January-November), compared to 52 during the same period last year. As we step ...
Deadline News
9 小时
£300k boost for research into ‘forgotten’ oesophageal cancer
Researchers from two universities will use a £300,000 grant from Ochre to study OSCC, a subtype of oesophageal cancer.
GlobalData on MSN
15 小时
UQ secures funds for development of skin cancer prevention cream
A research team at Australia's University of Queensland (UQ) has secured a A$344,000 grant from the National Foundation for ...
Business Wire
5 天
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...
1 天
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at ...
Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC– Conference call on ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈